Invent Medic publishes share issue page on its website

Today, Invent Medic publishes a share issue page on its website dedicated to collect information on the company’s preferential share issue with subscription period February 13-27 2020.

The share issue page includes information such as filmed company presentations, relevant news items from the company, prospectus and other documents as well as information on investor events during the subscription period.

A teaser document with a subscription form will be available when the subscription period begins on February 13.

The share issue page is available on https://www.inventmedic.se/en/share-issue/

The content on the share issue page will be updated continuously during the subscription period when new content becomes available.

For more information please contact
Karin Bryder, CEO
Phone: +46 (0)723811710
E-mail: info@inventmedic.com

About Invent Medic
Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women’s health and quality of life. The company’s products are to be safe, effective and easy to use. The finished women’s health products are sold through the company’s Arcamea brand. Invent Medic’s first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic’s share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share’s ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.